UY26118A1 - Efectos sinérgicos de la amlodipina y la atorvastatina o del metabolito de atorvastatina como base para terapia combinada. - Google Patents

Efectos sinérgicos de la amlodipina y la atorvastatina o del metabolito de atorvastatina como base para terapia combinada.

Info

Publication number
UY26118A1
UY26118A1 UY26118A UY26118A UY26118A1 UY 26118 A1 UY26118 A1 UY 26118A1 UY 26118 A UY26118 A UY 26118A UY 26118 A UY26118 A UY 26118A UY 26118 A1 UY26118 A1 UY 26118A1
Authority
UY
Uruguay
Prior art keywords
amlodipine
atorvastatine
metabolite
combined therapy
atorvastatin
Prior art date
Application number
UY26118A
Other languages
English (en)
Inventor
Dr Preston Mason
Original Assignee
Dr Preston Mason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY26118(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Preston Mason filed Critical Dr Preston Mason
Publication of UY26118A1 publication Critical patent/UY26118A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La combinación de amlodipina, ya sea con atorvastatina o con metabolito de atorvastatina, muestra un efecto sinérgico antioxidante en la peroxidación de lípidos de las lipo-proteínas humanas de baja densidad y en las vesículas de la membrana que tienen ácidos grasos ricos en enlaces no saturados. La inhibición del dano del radical-oxi por parte de esta combinación de fármacos, fue observada a niveles terapéuticos de una manera que no pudo ser reproducida mediante la combinación de amlodipina con otras astatinas o con el antioxidante natural, la vitamina E. La base de esta actividad fuerte es atribuida a las estructuras químicas de estos compuestos y sus interacciones moleculares con moléculas fosfolípidas, tal como lo determinan los análisis de difracción de rayos x. Dicha terapia combinada puede ser utilizada en el tratamiento de trastornos cardiovasculares, especialmente enfermedad de la arteria coronaria, al incrementar la resistencia de las lipo-proteínas de baja densidad y las membranas celulares vasculares contra las modificaciones de la oxidación
UY26118A 1999-04-23 2000-04-24 Efectos sinérgicos de la amlodipina y la atorvastatina o del metabolito de atorvastatina como base para terapia combinada. UY26118A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13066599P 1999-04-23 1999-04-23
US14530599P 1999-07-23 1999-07-23
US15112199P 1999-08-27 1999-08-27
US16659299P 1999-11-19 1999-11-19

Publications (1)

Publication Number Publication Date
UY26118A1 true UY26118A1 (es) 2001-03-16

Family

ID=27494873

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26118A UY26118A1 (es) 1999-04-23 2000-04-24 Efectos sinérgicos de la amlodipina y la atorvastatina o del metabolito de atorvastatina como base para terapia combinada.

Country Status (30)

Country Link
EP (1) EP1173172B1 (es)
JP (1) JP2002542289A (es)
KR (1) KR20020024581A (es)
CN (1) CN1351492A (es)
AP (1) AP2001002324A0 (es)
AT (1) ATE314846T1 (es)
AU (1) AU4647000A (es)
BG (1) BG106115A (es)
BR (1) BR0010689A (es)
CA (1) CA2370639A1 (es)
CZ (1) CZ20013793A3 (es)
DE (1) DE60025344T2 (es)
DK (1) DK1173172T3 (es)
EA (1) EA004435B1 (es)
EE (1) EE200100555A (es)
ES (1) ES2256005T3 (es)
HK (1) HK1043741A1 (es)
HU (1) HUP0201016A3 (es)
IL (1) IL146085A0 (es)
IS (1) IS6118A (es)
NO (1) NO20015128L (es)
OA (1) OA11870A (es)
PE (1) PE20010055A1 (es)
PL (1) PL351408A1 (es)
PT (1) PT1173172E (es)
SK (1) SK15382001A3 (es)
SV (1) SV2002000058A (es)
TN (1) TNSN00085A1 (es)
UY (1) UY26118A1 (es)
WO (1) WO2000064443A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
CN100430057C (zh) * 2005-04-08 2008-11-05 石药集团中奇制药技术（石家庄）有限公司 左旋氨氯地平和阿托伐他汀的药物组合物
KR101467110B1 (ko) * 2013-08-01 2014-11-28 한국방송공사 코로나링을 구비한 지선애자

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
AU4647000A (en) 2000-11-10
WO2000064443A9 (en) 2002-08-29
WO2000064443A1 (en) 2000-11-02
CA2370639A1 (en) 2000-11-02
KR20020024581A (ko) 2002-03-30
CN1351492A (zh) 2002-05-29
TNSN00085A1 (fr) 2005-11-10
HUP0201016A3 (en) 2003-03-28
SK15382001A3 (sk) 2002-05-09
SV2002000058A (es) 2002-02-05
PL351408A1 (en) 2003-04-22
HUP0201016A2 (hu) 2002-07-29
HK1043741A1 (zh) 2002-09-27
NO20015128D0 (no) 2001-10-19
PE20010055A1 (es) 2001-01-30
AP2001002324A0 (en) 2001-12-31
BR0010689A (pt) 2002-02-19
IL146085A0 (en) 2002-07-25
EP1173172A1 (en) 2002-01-23
BG106115A (bg) 2002-11-29
EA200101112A1 (ru) 2002-06-27
PT1173172E (pt) 2006-05-31
EE200100555A (et) 2002-12-16
JP2002542289A (ja) 2002-12-10
OA11870A (en) 2006-03-27
IS6118A (is) 2001-10-19
NO20015128L (no) 2001-12-20
ATE314846T1 (de) 2006-02-15
CZ20013793A3 (cs) 2002-05-15
EP1173172A4 (en) 2002-08-07
EP1173172B1 (en) 2006-01-04
DK1173172T3 (da) 2006-05-15
ES2256005T3 (es) 2006-07-16
EA004435B1 (ru) 2004-04-29
DE60025344T2 (de) 2006-09-28
DE60025344D1 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
US6528040B1 (en) EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
JP7242718B2 (ja) ザクロ種子油、ｒｏｓａ ｃａｎｉｎａ果実油、およびｉｎｕｌａ ｖｉｓｃｏｓａ含油樹脂または抽出物を含有する製剤
Jackson et al. Application of low‐level laser therapy for noninvasive body contouring
AU2002324481A1 (en) Emu-based formulations for wound treatment related application information
HU226673B1 (en) Use of essential fatty acids and bioactive disulphides for the preparation of therapeutic and dietary compositions
UY26118A1 (es) Efectos sinérgicos de la amlodipina y la atorvastatina o del metabolito de atorvastatina como base para terapia combinada.
dos Santos Borges et al. Fundamentals of the use of ozone therapy in the treatment of aesthetic disorders: A review
ES2035092T3 (es) Producto liquido para el tratamiento estetico de la piel y su procedimiento de fabricacion.
US4983625A (en) Psoralene-based bath compositions for treatment of skin disorders
JP2006176471A (ja) ユビキノン類を有効成分とする遅効性又は持続性化粧料又はパック用貼付剤。
ECSP003442A (es) Efectos sinergeticos de amlodipina y atorvastatina o metabolito de atorvastatina como una base para la terapia de combinacion
AR023569A1 (es) Efectos sinergicos de la amlodipina y atorvastatina o metabolitos de la atorvastatina, como base para una terapia combinada
JPH01502907A (ja) 主に皮膚科学および化粧料用のエステラーゼ産生微生物抑制剤
Price How essential oils enter the body
US20170281581A1 (en) Sports health performance composition background
US20190365735A1 (en) Compositions and methods for treating varicose veins
Merker Benzoyl peroxide: a history of early research and researchers.
JP2006248953A (ja) シワ改善剤及び皮膚外用組成物
Basto et al. Contact dermatitis due to incense.
ES2333641T3 (es) Utilizacion de lipidos peroxidados para prevenir y/o tratar los efectos irritantes de un principio activo.
US20210338756A1 (en) Healing creams and formulations containing pomegranate seed oil, rosa canina fruit oil, inula viscosa oleoresin or extract and optionally citrus medica vulgaris etrog oil or extract
WILLIAMS Pharmaceutical solvents as vehicles for topical dosage forms
Goyal et al. Formulation and Evaluation of Niosomal Gel for Treatment of Acne
Kang et al. Terpenes and Improvement of Transdermal Drug Delivery
Dalvi et al. FORMULATION AND EVALUATION OF VITA-C SERUM

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20090417